Citadel Advisors
NPCE icon

Citadel Advisors’s Neuropace NPCE Stock Holding History

Citadel Advisors’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.15M Sell
87,284
-44,575
-34% -$669K ﹤0.01% 7342
2025
Q4 		$2.04M Buy
+131,859
New +$1.76M ﹤0.01% 5865
2025
Q2 		– Sell
-123,346
Closed -$1.54M – 14238
2025
Q1 		$1.52M Buy
123,346
+84,739
+219% +$1.06M ﹤0.01% 6078
2024
Q4 		$432K Buy
38,607
+22,126
+134% +$192K ﹤0.01% 8886
2024
Q3 		$115K Sell
16,481
-20,631
-56% -$151K ﹤0.01% 10933
2024
Q2 		$281K Buy
37,112
+28,962
+355% +$292K ﹤0.01% 9272
2024
Q1 		$108K Sell
8,150
-15,905
-66% -$227K ﹤0.01% 11255
2023
Q4 		$248K Buy
+24,055
New +$192K ﹤0.01% 9538
2022
Q3 		– Sell
-21,692
Closed -$108K – 13272
2022
Q2 		$108K Buy
+21,692
New +$143K ﹤0.01% 11337
2022
Q1 		– Sell
-10,009
Closed -$101K – 14256
2021
Q4 		$101K Sell
10,009
-15,813
-61% -$205K ﹤0.01% 12717
2021
Q3 		$410K Buy
+25,822
New +$542K ﹤0.01% 10353

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Citadel Advisors's NPCE Position: Q1 2026 in Review

Citadel Advisors reduced its Neuropace (NPCE) stake by 34% in Q1 2026, selling an estimated $669K and leaving 87,284 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #7342.

Citadel Advisors first reported a position in NPCE in Q3 2021 and has held it in 11 quarters since. The position peaked at $2.04M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Citadel Advisors held 87,284 shares of Neuropace worth $1.15M as of Q1 2026.
  • Citadel Advisors sold 44,575 Neuropace shares in Q1 2026, an estimated $669K.
  • Neuropace made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7342 holding.
  • Citadel Advisors first reported a position in Neuropace in Q3 2021 and has held it in 11 quarters since.
  • Citadel Advisors's Neuropace position peaked at $2.04M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.